68 related articles for article (PubMed ID: 38456678)
1. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Eshmuminov D; Aminjonov B; Palm RF; Malleo G; Schmocker RK; Abdallah R; Yoo C; Shaib WL; Schneider MA; Rangelova E; Choi YJ; Kim H; Rose JB; Patel S; Wilson GC; Maloney S; Timmermann L; Sahora K; Rössler F; Lopez-Lopez V; Boyer E; Maggino L; Malinka T; Park JY; Katz MHG; Prakash L; Ahmad SA; Helton S; Jang JY; Hoffe SE; Salvia R; Taieb J; He J; Clavien PA; Held U; Lehmann K
Ann Surg Oncol; 2023 Jul; 30(7):4417-4428. PubMed ID: 37020094
[TBL] [Abstract][Full Text] [Related]
2. The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Conroy T; Gavoille C; Samalin E; Ychou M; Ducreux M
Curr Oncol Rep; 2013 Apr; 15(2):182-9. PubMed ID: 23341367
[TBL] [Abstract][Full Text] [Related]
3. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study.
Theijse RT; Stoop TF; Janssen QP; Prakash LR; Katz MHG; Doppenberg D; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38456678
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
7. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer.
Stoop TF; Theijse RT; Seelen LWF; Groot Koerkamp B; van Eijck CHJ; Wolfgang CL; van Tienhoven G; van Santvoort HC; Molenaar IQ; Wilmink JW; Del Chiaro M; Katz MHG; Hackert T; Besselink MG;
Nat Rev Gastroenterol Hepatol; 2024 Feb; 21(2):101-124. PubMed ID: 38036745
[TBL] [Abstract][Full Text] [Related]
9. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study.
Seelen LWF; Doppenberg D; Stoop TF; Nagelhout A; Brada LJH; Bosscha K; Busch OR; Cirkel GA; den Dulk M; Daams F; van Dieren S; van Eijck CHJ; Festen S; Groot Koerkamp B; Haj Mohammad N; de Hingh IHJT; Lips DJ; Los M; de Meijer VE; Patijn GA; Polée MB; Stommel MWJ; Walma MS; de Wilde RF; Wilmink JW; Molenaar IQ; van Santvoort HC; Besselink MG;
Ann Surg; 2024 May; 279(5):832-841. PubMed ID: 37477009
[TBL] [Abstract][Full Text] [Related]
10. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial.
van Dongen JC; Versteijne E; Bonsing BA; Mieog JSD; de Hingh IHJT; Festen S; Patijn GA; van Dam R; van der Harst E; Wijsman JH; Bosscha K; van der Kolk M; de Meijer VE; Liem MSL; Busch OR; Besselink MGH; van Tienhoven G; Groot Koerkamp B; van Eijck CHJ; Suker M;
Eur J Surg Oncol; 2023 Apr; 49(4):811-817. PubMed ID: 36585300
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and risks in palliative pancreatic surgery: an analysis of the German StuDoQ|Pancreas registry.
Hofmann FO; Miksch RC; Weniger M; Keck T; Anthuber M; Witzigmann H; Nuessler NC; Reissfelder C; Köninger J; Ghadimi M; Bartsch DK; Hartwig W; Angele MK; D'Haese JG; Werner J
BMC Surg; 2022 Nov; 22(1):389. PubMed ID: 36368993
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
13. Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy: An International Multicenter Study.
Seelen LWF; Floortje van Oosten A; Brada LJH; Groot VP; Daamen LA; Walma MS; van der Lek BF; Liem MSL; Patijn GA; Stommel MWJ; van Dam RM; Koerkamp BG; Busch OR; de Hingh IHJT; van Eijck CHJ; Besselink MG; Burkhart RA; Borel Rinkes IHM; Wolfgang CL; Molenaar IQ; He J; van Santvoort HC
Ann Surg; 2023 Jul; 278(1):118-126. PubMed ID: 35950757
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
